Annovis Bio to Present Comprehensive Buntanetap Data at Parkinson Study Group Meeting
Annovis Bio will present new Phase 3 findings showing buntanetap reverses cognitive decline in Parkinson's patients with amyloid co-pathology while reducing tau biomarkers, offering the most comprehensive view to date of cognitive outcomes across neurodegenerative disease trials.
Read the full story

























